FOLH1 and neoplasm: In a recently published clinical study, ten patients with metastatic castration resistant prostate cancer (mCRPC) received [177Lu]Lu-PSMA-ALB-56 endoradiotherapy with a higher absorbed dose in tumor lesions and similar salivary gland-uptake compared to PSMA-617 and PSMA I&T [155].